Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.65 |
| ▸ | CES1 | P23141 | 1/20 | 0.65 |
| ▸ | PARP1 | P09874 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
| ▸ | MGLL | Q99685 | 1/20 | 0.59 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31636008 | 1.00 | CES2 (0.65) | CES2CES1PARP1NPC1RAB9A | |
| SCHEMBL18360283 | 0.93 | KDM2B (0.62) | CES2CES1PARP1NPC1RAB9A | |
| SCHEMBL6208933 | 0.90 | CES2 (0.57) | CES2CES1PARP1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL16432038 | 0.89 | HTR2C (0.57) | CES2CES1PARP1NPC1RAB9A | |
| SCHEMBL5210032 | 0.88 | MGLL (0.62) | CES2CES1PARP1HSD11B1MGLL | |
| SCHEMBL30771226 | 0.88 | MGLL (0.62) | CES2CES1PARP1HSD11B1MGLL | |
| SCHEMBL2992325 | 0.88 | CES2 (0.54) | CES2CES1PARP1NPC1RAB9A | |
| SCHEMBL20934473 | 0.88 | CES2 (0.54) | CES2CES1PARP1NPC1RAB9A | |
| SCHEMBL20934574 | 0.88 | CES2 (0.54) | CES2CES1PARP1NPC1RAB9A | |
| SCHEMBL2992324 | 0.88 | CES2 (0.54) | CES2CES1PARP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137310-A1 | CRYSTALLINE GPR40 AGONIST AND METHODS OF MAKING | KALLYOPE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-119118807-A | Method for synthesizing aryl butanone by ligand-regulated nickel-catalyzed aryl cyclopropyl ketone ring-opening hydrogenation | 陕西师范大学 | 2024-12-13 | — | — | CN | disclosed |
| EP-3061756-B1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-9635857-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-9635857-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-9635857-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-3061756-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-3061756-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| WO-2015060461-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | 住友化学株式会社 | 2015-04-30 | — | — | WO | disclosed |
| US-4596872-A | Imidazo[1,2-a]pyridines, and process for their preparation | SCHERING A.G. (DE) | 1986-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235065-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | MRPS17, TAOK1, TAOK3 | CES2 2030/4885CES1 2104/4885PARP1 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.